Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review
Open Access
Abstract
Objectives This study examined patient adherence and persistence to oral bisphosphonates for the treatment of osteoporosis in real-world settings. Methods A systematic review was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Medical Literature Analysis and Retrieval System Online (MEDLINE), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Allied and Complementary Medicine Database (AMED), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA) and National Health Service Economic Evaluation Database NHS EED) databases were searched for studies published in English language up to April 2018. Prospective and retrospective observational studies that used prescription claim databases or hospital medical records to examine patient adherence and persistence to oral bisphosphonate treatment among adults with osteoporosis were included. The Newcastle–Ottawa quality assessment scale (NOS) was used to assess the quality of included studies. Results The search yielded 540 published studies, of which 89 were deemed relevant and were included in this review. The mean age of patients included within the studies ranged between 53 to 80.8 years, and the follow-up varied from 3 months to 14 years. The mean persistence of oral bisphosphonates for 6 months, 1 year and 2 years ranged from 34.8% to 71.3%, 17.7% to 74.8% and 12.9% to 72.0%, respectively. The mean medication possession ratio ranged from 28.2% to 84.5%, 23% to 50%, 27.2% to 46% over 1 year, 2 years and 3 years, respectively. All studies included scored between 6 to 8 out of 9 on the NOS. The determinants of adherence and persistence to oral bisphosphonates included geographic residence, marital status, tobacco use, educational status, income, hospitalisation, medication type and dosing frequency. Conclusions While a number of studies reported high levels of persistence and adherence, the findings of this review suggest that patient persistence and adherence with oral bisphosphonates medications was poor and reduced notably over time. Overall, adherence was suboptimal. To maximise adherence and persistence to oral bisphosphonates, it is important to consider possible determinants, including characteristics of the patients.Keywords
This publication has 112 references indexed in Scilit:
- Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, CanadaOsteoporosis International, 2011
- Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The NetherlandsOsteoporosis International, 2010
- Bisphosphonates for the treatment of osteoporosis: insights for cliniciansTherapeutic Advances in Chronic Disease, 2010
- Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniorsOsteoporosis International, 2010
- Adoption of Once-monthly Oral Bisphosphonates and the Impact on AdherenceThe American Journal of Medicine, 2010
- Adherence to monthly and weekly oral bisphosphonates in women with osteoporosisOsteoporosis International, 2009
- Improving the Prediction of Medication ComplianceMedical Care, 2009
- Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holidayOsteoporosis International, 2008
- Loss of treatment benefit due to low compliance with bisphosphonate therapyOsteoporosis International, 2007
- A prospective study of discordance in diagnosis of osteoporosis using spine and proximal femur bone densitometryOsteoporosis International, 2003